TransMedics Group (NASDAQ:TMDX) Price Target Raised to $130.00

TransMedics Group (NASDAQ:TMDX) had its target price boosted by Stifel Nicolaus from $115.00 to $130.00 in a report issued on Monday morning,Benzinga reports. They currently have a hold rating on the stock.

Other analysts have also recently issued research reports about the company. Oppenheimer raised their price target on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price objective on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Wall Street Zen cut shares of TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, Needham & Company LLC lifted their target price on shares of TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $152.33.

TransMedics Group Trading Down 1.4%

Shares of TMDX stock opened at $128.97 on Monday. The company has a market capitalization of $4.42 billion, a PE ratio of 26.32 and a beta of 1.98. TransMedics Group has a 52-week low of $62.23 and a 52-week high of $156.00. The business’s fifty day moving average is $135.91 and its 200 day moving average is $127.17. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14.

Insider Transactions at TransMedics Group

In related news, insider Nicholas Corcoran sold 2,966 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $412,629.92. Following the transaction, the insider directly owned 29,831 shares of the company’s stock, valued at approximately $4,150,088.72. This trade represents a 9.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Stephanie Lovell sold 1,193 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total value of $178,496.66. Following the completion of the sale, the director owned 2,866 shares of the company’s stock, valued at $428,810.92. The trade was a 29.39% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 16,205 shares of company stock worth $2,353,002. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TMDX. Whittier Trust Co. of Nevada Inc. boosted its stake in shares of TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new position in shares of TransMedics Group during the 3rd quarter valued at $28,000. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group in the 3rd quarter worth $29,000. Optiver Holding B.V. lifted its stake in TransMedics Group by 248.1% in the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after purchasing an additional 191 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.